182 related articles for article (PubMed ID: 32354686)
1. Immunotherapy rechallenge in patients with non-small-cell lung cancer.
España S; Guasch I; Carcereny E
Pulmonology; 2020; 26(4):252-254. PubMed ID: 32354686
[No Abstract] [Full Text] [Related]
2. Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma.
Irifuku T; Satoh A; Tani H; Mandai K; Masaki T
CEN Case Rep; 2020 Feb; 9(1):48-54. PubMed ID: 31605271
[TBL] [Abstract][Full Text] [Related]
3. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.
McClure T; Cui W; Asadi K; John T; Testro A
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32912846
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Kim YJ; Oremus M; Chen HH; McFarlane T; Shah D; Horton S
Future Oncol; 2020 Sep; 16(27):2045-2058. PubMed ID: 32598192
[No Abstract] [Full Text] [Related]
5. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
[TBL] [Abstract][Full Text] [Related]
6. Safety of current immune checkpoint inhibitors in non-small cell lung cancer.
Abdayem P; Planchard D
Expert Opin Drug Saf; 2021 Jun; 20(6):651-667. PubMed ID: 33393387
[No Abstract] [Full Text] [Related]
7. [A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1
Antibody-Safety and Effectiveness of Pirfenidone].
Yu H; Li J; Yu L; Cheng X; Han X; Zhang X
Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):519-525. PubMed ID: 34134189
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.
Canale ML; Camerini A; Casolo G; Lilli A; Bisceglia I; Parrini I; Lestuzzi C; Del Meglio J; Puccetti C; Camerini L; Amoroso D; Maurea N
Adv Ther; 2020 Jul; 37(7):3178-3184. PubMed ID: 32436027
[TBL] [Abstract][Full Text] [Related]
9. Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment.
Samejima Y; Iuchi A; Kanai T; Noda Y; Nasu S; Tanaka A; Morishita N; Suzuki H; Okamoto N; Harada H; Ezumi A; Ueda K; Kawahara K; Hirashima T
Intern Med; 2020 Aug; 59(16):2003-2008. PubMed ID: 32448839
[TBL] [Abstract][Full Text] [Related]
10. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
Hirasawa Y; Yoshimura K; Matsui H; Kubota Y; Ishida H; Arai J; Sakaki M; Oguro N; Shida M; Taniguchi M; Hamada K; Ariizumi H; Ishiguro T; Ohkuma R; Sambe T; Horiike A; Imamura CK; Shiozawa E; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Tate G; Kobayashi S; Tsunoda T
Medicine (Baltimore); 2021 Jun; 100(23):e25774. PubMed ID: 34114983
[TBL] [Abstract][Full Text] [Related]
11. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
[TBL] [Abstract][Full Text] [Related]
12. [Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC].
El-Ghazzi N; Lavaud P
Bull Cancer; 2021 Mar; 108(3):231-233. PubMed ID: 33622569
[No Abstract] [Full Text] [Related]
13. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
14. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.
Cascone T; Weissferdt A; Godoy MCB; William WN; Leung CH; Lin HY; Basu S; Yadav SS; Pataer A; Mitchell KG; Khan MAW; Shi Y; Haymaker C; Solis LM; Parra ER; Kadara H; Wistuba II; Sharma P; Allison JP; Ajami NJ; Wargo JA; Jenq RR; Gibbons DL; Lee JJ; Swisher SG; Vaporciyan AA; Heymach JV; Sepesi B
Nat Commun; 2021 Aug; 12(1):5045. PubMed ID: 34413300
[TBL] [Abstract][Full Text] [Related]
15. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
[No Abstract] [Full Text] [Related]
16. Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer.
Jensen KH; Persson G; Bondgaard AL; Pøhl M
Acta Oncol; 2018 Aug; 57(8):1127-1128. PubMed ID: 29384034
[No Abstract] [Full Text] [Related]
17. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
18. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
[TBL] [Abstract][Full Text] [Related]
19. IMMUNE RETINOPATHY ASSOCIATED WITH NIVOLUMAB ADMINISTRATION FOR METASTATIC NON-SMALL CELL LUNG CANCER.
Reddy M; Chen JJ; Kalevar A; Terribilini R; Agarwal A
Retin Cases Brief Rep; 2020; 14(2):120-126. PubMed ID: 29176534
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab.
Yamaguchi O; Kaira K; Hashimoto K; Mouri A; Miura Y; Shiono A; Nishihara F; Murayama Y; Noda SE; Kato S; Kobayashi K; Kagamu H
Thorac Cancer; 2019 Apr; 10(4):992-1000. PubMed ID: 30888716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
